Processa Registers 306.6M Shares for Resale by PIPE and Merger Investors
PCSA sits 41% above its 52-week low of $1.041 on elevated volume (11× avg).
Summary
Processa filed an S-3 to register 306.6 million shares for resale by investors from its July 2026 Vidya merger and $200M PIPE. The company receives no proceeds; the filing makes the overhang tradable and discloses plans to rename to Vidya Therapeutics (ticker VDYA).
Key Events · Financing and Capital Events · PCSA
-
306.6M Shares Registered for Resale
The S-3 registers 306,574,202 shares of common stock for resale by selling stockholders — 142.3M merger conversion shares, 163.8M private placement conversion shares, and 544,551 Tungsten conversion shares.
-
No Proceeds to Company
Processa will not receive any proceeds from the resale. The filing fee table values the registered shares at $1.52 each (Nasdaq average on October 6, 2026), implying a maximum aggregate offering price of approximately $465.99 million.
-
Conversion Subject to Stockholder Approval
Each Series A Preferred share converts into 1,000 common shares, but only after stockholder approval of the Conversion Proposal and subject to beneficial ownership limitations of 4.99% to 19.99% per holder.
-
Name Change to Vidya Therapeutics Planned
Upon approval of the Required Company Stockholder Matters and Nasdaq Listing Application, the company expects to change its name to Vidya Therapeutics, Inc. and trade under ticker 'VDYA'.
Analysis · PCSA · Life Sciences
This S-3 registers 306,574,202 shares for resale by the selling stockholders from the July 2026 Vidya merger and $200 million PIPE. The shares are issuable upon conversion of Series A Preferred Stock at a 1,000-to-1 ratio, subject to stockholder approval of the Conversion Proposal. The filing fee table values the shares at $1.52 each, implying a maximum aggregate offering price of approximately $466 million. The company will not receive any proceeds — this is purely a resale registration that makes the overhang tradable. The filing also discloses that the company intends to change its name to Vidya Therapeutics, Inc. and trade under ticker 'VDYA' upon approval of the Required Company Stockholder Matters and Nasdaq Listing Application. The 180-day lock-up period from the July 28, 2026 closing has not yet expired, so actual sales cannot begin until late January 2027 at the earliest.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 28.2% of the 1631 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCSA was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $1.04 to $11.08. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.